SS-31 (Elamipretide)

Overview

SS-31 (elamipretide) is a synthetic tetrapeptide — a chain of four amino acids — that belongs to an emerging class of therapeutics designed to act directly on mitochondria, the structures that produce most of a cell’s energy. It is distinctive for concentrating in the inner mitochondrial membrane, where it associates with cardiolipin, a phospholipid essential to mitochondrial structure.

Interest in SS-31 spans cardiovascular, neurological, ophthalmic, and age-related contexts, largely because mitochondrial decline is a common thread across many of these conditions. Much of the supporting work comes from preclinical models, alongside a growing body of human clinical trials.

In 2025 elamipretide received FDA accelerated approval as Forzinity for Barth syndrome, a rare inherited mitochondrial disorder — the first approval of a mitochondria-targeted peptide. Outside that narrow indication, its use in longevity and wellness settings remains investigational.

How it works

SS-31 is designed to enter the inner mitochondrial membrane and bind reversibly to cardiolipin. In preclinical studies this association is reported to help stabilize the folded membrane structures called cristae and support the efficiency of the electron transport chain, which cells use to generate energy. By modulating cardiolipin interactions, researchers propose the peptide may reduce oxidative stress and help preserve mitochondrial function under stress.

Studies have also described SS-31 altering the surface electrostatics of mitochondrial membranes and interacting with proteins involved in energy production. The precise mechanism, and how fully it translates to humans outside of approved indications, is still being characterized.

Reported benefits

• Support for cellular energy production via improved mitochondrial function (largely preclinical and trial data)
• Reduced markers of oxidative stress in research settings
• Studied for cardiac function in heart-failure and rare mitochondrial-disease trials
• Investigated for age-related eye conditions and neurological aging

These are reported and studied effects, not guaranteed outcomes, and much of the evidence outside of Barth syndrome remains preliminary.

Considerations & side effects

Because human evidence outside its approved rare-disease indication is still emerging, the long-term safety profile of SS-31 for general wellness or anti-aging use is not well established. In clinical trials the most commonly reported side effects have been injection-site reactions.

Product purity varies widely in the research-chemical market, and material sold for research is not manufactured to pharmaceutical standards. SS-31 is not a substitute for evaluation and treatment by a qualified clinician.